Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4401603 | 0.81 | DYRK1A (0.47) | DYRK1ALCKKDRJAK3MAPK14 | |
| SCHEMBL4399087 | 0.80 | LCK (0.45) | DYRK1ALCKKDRJAK3MAPK14 | |
| SCHEMBL4397389 | 0.78 | QPCT (0.45) | LCKKDRJAK3MAPK14DHFR | |
| SCHEMBL6313258 | 0.77 | DYRK1A (0.43) | DYRK1AVRK1PFKFB3TGFBR1ADORA1 | |
| SCHEMBL31403185 | 0.76 | TOP2A (0.46) | DYRK1AVRK1PFKFB3TGFBR1IRAK4 | |
| SCHEMBL4400611 | 0.76 | TNIK (0.38) | LCKKDRJAK3MAPK14ADORA1 | |
| SCHEMBL4398362 | 0.76 | MAP3K11 (0.49) | DYRK1ALCKKDRJAK3MAPK14 | |
| SCHEMBL4393565 | 0.76 | MAPKAPK2 (0.52) | DYRK1AMAPK14TGFBR1DYRK2 | |
| SCHEMBL4396796 | 0.75 | LCK (0.38) | LCKKDRJAK3MAPK14ADORA1 | |
| SCHEMBL30945399 | 0.75 | DYRK1A (0.56) | DYRK1ALCKKDRJAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | claimed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | claimed |
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| WO-2007075911-A2 | INHIBITION OF GLYCOGEN SYNTHASE KINASE AND METHODS OF TREATING AUTOIMMUNE OR IMMUNE INFLAMMATORY DISEASE | YALE UNIVERSITY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | GSK3B, GSK3A, GSKIP | DYRK1A 69/4885LCK 146/4885KDR 2342/4885 |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | DYRK1A 304/4885LCK 1894/4885KDR 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.